• roche logo

The potential to set the new standard of care in cervical cancer screening. 

The cobas® HPV Test provides significantly enhanced patient risk stratification.1,2

Based on the ATHENA data, a clinical utility model of the HPV primary screening algorithm was developed for the detection of cervical disease (≥CIN3) over a 3-yr follow-up period. In women ages 25 and older, HPV primary screening with the cobas® HPV Test detected 33% more cases of ≥CIN3 than cytology with reflex HPV. Learn more below by comparing the HPV primary screening algorithm with other screening strategies.

HPV primary screening algorithm with the cobas® HPV Test

  • Detected 33% more ≥CIN3 cases than cytology with HPV reflex 
  • Minimal increase to number of colposcopies per case of ≥CIN3 detected

† Model assumptions:

  1. No regression of ≥CIN2 during the first year
  2. All HPV positive ≥CIN2 were persistently HPV positive at year 1
  3. Women complied with colposcopy when indicated at year 1

The cobas® HPV Test. An evidence-based approach to primary screening. 

Help protect women from cervical cancer and identify those at highest risk.

Based on the results from the ATHENA study, the optimal primary screening strategy focuses medical attention on women with HPV 16 and HPV 18 genotypes, and triages other high-risk genotypes, balancing detected cases and intervention.1,5 HPV DNA testing permits confident extension of screening intervals and identifies women who can return to routine screening.6

The cobas® HPV Test:

  • Enables clinicians to use pooled HPV testing with or without individual HPV 16/18 genotyping to achieve significant advantages over the current standard of care1
  • Allows early and efficient stratification of the few women who require aggressive intervention and those who are at very low risk1
  • Finds more cases of disease while reducing the burden on the healthcare system, compared to cytology-based screening, through the use of simultaneous HPV 16/18 genotyping1


Learn more about the cobas® HPV Test

  • Acronyms:


1. Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Ob Gyn. 2012:In Press.

Wright TC, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet & Gynecol. 2012;206:46.e1-11.

3. Data on file, Roche Molecular Systems, Inc.

4. Herzog TJ, Monk BH. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197:566-571.

5. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection for high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012; 13:78-88. 

6. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663- 672.